HK1253558A1 - 法尼醇x受體調節劑 - Google Patents
法尼醇x受體調節劑Info
- Publication number
- HK1253558A1 HK1253558A1 HK18112762.1A HK18112762A HK1253558A1 HK 1253558 A1 HK1253558 A1 HK 1253558A1 HK 18112762 A HK18112762 A HK 18112762A HK 1253558 A1 HK1253558 A1 HK 1253558A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- farnesoid
- receptor modulators
- modulators
- receptor
- Prior art date
Links
- 102100038495 Bile acid receptor Human genes 0.000 title 1
- 101000603876 Homo sapiens Bile acid receptor Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
- C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
- C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562238246P | 2015-10-07 | 2015-10-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1253558A1 true HK1253558A1 (zh) | 2019-06-21 |
Family
ID=58488545
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK18112762.1A HK1253558A1 (zh) | 2015-10-07 | 2018-10-08 | 法尼醇x受體調節劑 |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US11034717B2 (zh) |
| EP (2) | EP3359160B1 (zh) |
| JP (2) | JP7021080B2 (zh) |
| KR (1) | KR20180061351A (zh) |
| CN (1) | CN108348530B (zh) |
| AR (1) | AR106293A1 (zh) |
| AU (1) | AU2016335765B2 (zh) |
| BR (1) | BR112018006892B1 (zh) |
| CA (1) | CA3000881C (zh) |
| CL (1) | CL2018000883A1 (zh) |
| CO (1) | CO2018003728A2 (zh) |
| CR (1) | CR20180201A (zh) |
| DK (1) | DK3359160T3 (zh) |
| EA (1) | EA038665B1 (zh) |
| EC (1) | ECSP18030284A (zh) |
| ES (1) | ES2898705T3 (zh) |
| HK (1) | HK1253558A1 (zh) |
| IL (1) | IL258359B2 (zh) |
| MA (2) | MA42339A1 (zh) |
| MX (1) | MX2018004186A (zh) |
| PH (1) | PH12018500777A1 (zh) |
| SV (1) | SV2018005662A (zh) |
| TN (1) | TN2018000106A1 (zh) |
| TW (1) | TW201718621A (zh) |
| UA (1) | UA123948C2 (zh) |
| WO (1) | WO2017062763A1 (zh) |
| ZA (1) | ZA201802901B (zh) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017533923A (ja) | 2014-11-06 | 2017-11-16 | エナンタ ファーマシューティカルズ インコーポレイテッド | Ｆｘｒ／ｔｇｒ５アゴニストとしての胆汁酸類似体およびその使用方法 |
| US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| US11578097B2 (en) | 2014-11-26 | 2023-02-14 | Enanta Pharmaceuticals, Inc. | Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof |
| RU2017121457A (ru) | 2014-11-26 | 2018-12-26 | Энанта Фармасьютикалс, Инк. | Аналоги желчной кислоты в качестве агонистов fxr/tgr5 и способы их применения |
| SG11201706089RA (en) | 2015-02-11 | 2017-09-28 | Enanta Pharm Inc | Bile acid analogs as fxr/tgr5 agonists and methods of use thereof |
| SG10201910670RA (en) | 2015-03-31 | 2020-01-30 | Enanta Pharm Inc | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof |
| EP3359160B1 (en) * | 2015-10-07 | 2021-08-25 | Intercept Pharmaceuticals, Inc. | Farnesoid x receptor modulators |
| US10323060B2 (en) | 2016-02-23 | 2019-06-18 | Enanta Pharmaceuticals, Inc. | Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof |
| US10364267B2 (en) | 2016-02-23 | 2019-07-30 | Enanta Pharmaceuticals, Inc. | Deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| WO2017147174A1 (en) | 2016-02-23 | 2017-08-31 | Enanta Pharmaceuticals, Inc. | Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof |
| CN110121347A (zh) | 2016-11-29 | 2019-08-13 | 英安塔制药有限公司 | 制备磺酰脲胆汁酸衍生物的方法 |
| WO2018152171A1 (en) | 2017-02-14 | 2018-08-23 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as fxr agonists and methods of use thereof |
| WO2018187804A1 (en) | 2017-04-07 | 2018-10-11 | Enanta Pharmaceuticals, Inc. | Process for preparation of sulfonyl carbamate bile acid derivatives |
| IL271343B2 (en) * | 2017-06-23 | 2023-12-01 | Intercept Pharmaceuticals Inc | Methods and intermediates for the preparation of bile acid derivatives |
| MX2020000873A (es) | 2017-07-24 | 2020-07-22 | Intercept Pharmaceuticals Inc | Derivados de ácidos biliares marcados isotópicamente. |
| CN109929005B (zh) * | 2017-12-19 | 2020-10-30 | 西安奥立泰医药科技有限公司 | 用于代谢性疾病治疗的化合物及其制备方法和应用 |
| GB201812382D0 (en) | 2018-07-30 | 2018-09-12 | Nzp Uk Ltd | Compounds |
| WO2020243590A1 (en) | 2019-05-30 | 2020-12-03 | Intercept Pharmaceuticals, Inc. | Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease |
| WO2023288123A1 (en) | 2021-07-16 | 2023-01-19 | Interecept Pharmaceuticals, Inc. | Methods and intermediates for the preparation of 3.alpha.,7.alpha.,11.beta.-trihydroxy-6.alpha.-ethyl-5.beta.-cholan-24-oic acid |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2599481A (en) * | 1948-09-28 | 1952-06-03 | Ciba Pharm Prod Inc | Reduction of steroid epoxides |
| DE3366932D1 (en) * | 1982-07-29 | 1986-11-20 | Lehner Ag | New derivatives of biliary acids, process for the production thereof and pharmaceutical compositions containing the same |
| IT1223313B (it) | 1987-10-20 | 1990-09-19 | Gipharmex Spa | Derivati di acidi biliari loro preparazione e composizioni farmaceutiche che li contengono |
| DE10113257C1 (de) | 2001-03-19 | 2002-11-14 | Inst Mikrotechnik Mainz Gmbh | Elektrophoresevorrichtung und ihre Verwendung |
| US20070197484A1 (en) * | 2001-05-03 | 2007-08-23 | Ching Song | Method of treating disorder related to high cholesterol concentration |
| PL2040713T3 (pl) * | 2006-06-27 | 2014-11-28 | Intercept Pharmaceuticals Inc | Pochodne kwasów żółciowych jako ligandy FXR do zapobiegania lub leczenia chorób lub stanów, w których pośredniczy FXR |
| MX2011005295A (es) * | 2008-11-19 | 2011-06-24 | Intercept Pharmaceuticals Inc | Moduladores de tgr5 y metodo de uso de los mismos. |
| SG11201408501UA (en) | 2012-06-19 | 2015-01-29 | Intercept Pharmaceuticals Inc | Preparation, uses and solid forms of obeticholic acid |
| EP2925328A1 (en) | 2012-11-28 | 2015-10-07 | Intercept Pharmaceuticals, Inc. | Treatment of pulmonary disease |
| DK3848038T3 (da) * | 2013-05-14 | 2023-02-06 | Intercept Pharmaceuticals Inc | 11-Hydroxyl-6substituerede-derivater af galdesyrer og aminosyrerkonjugater heraf som farnesoid X receptor modulerer. |
| US9351083B2 (en) | 2013-10-17 | 2016-05-24 | Turtle Beach Corporation | Transparent parametric emitter |
| RU2017121457A (ru) * | 2014-11-26 | 2018-12-26 | Энанта Фармасьютикалс, Инк. | Аналоги желчной кислоты в качестве агонистов fxr/tgr5 и способы их применения |
| US11578097B2 (en) * | 2014-11-26 | 2023-02-14 | Enanta Pharmaceuticals, Inc. | Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof |
| EP3359160B1 (en) * | 2015-10-07 | 2021-08-25 | Intercept Pharmaceuticals, Inc. | Farnesoid x receptor modulators |
| CN108347941B (zh) | 2015-10-07 | 2021-06-01 | 斯托尔勒企业公司 | 使用含有二酰基脲或二芳基脲和至少一种金属配合物的具有协同作用的农业配方管理植物中的乙烯 |
| AU2017229481B2 (en) * | 2016-03-11 | 2022-06-16 | Intercept Pharmaceuticals, Inc. | 3-desoxy derivative and pharmaceutical compositions thereof |
| IL271343B2 (en) * | 2017-06-23 | 2023-12-01 | Intercept Pharmaceuticals Inc | Methods and intermediates for the preparation of bile acid derivatives |
-
2016
- 2016-10-07 EP EP16854420.3A patent/EP3359160B1/en active Active
- 2016-10-07 IL IL258359A patent/IL258359B2/en unknown
- 2016-10-07 TN TNP/2018/000106A patent/TN2018000106A1/en unknown
- 2016-10-07 DK DK16854420.3T patent/DK3359160T3/da active
- 2016-10-07 KR KR1020187012652A patent/KR20180061351A/ko not_active Application Discontinuation
- 2016-10-07 TW TW105132613A patent/TW201718621A/zh unknown
- 2016-10-07 MX MX2018004186A patent/MX2018004186A/es unknown
- 2016-10-07 BR BR112018006892-6A patent/BR112018006892B1/pt active IP Right Grant
- 2016-10-07 MA MA42339A patent/MA42339A1/fr unknown
- 2016-10-07 CN CN201680063616.0A patent/CN108348530B/zh active Active
- 2016-10-07 CR CR20180201A patent/CR20180201A/es unknown
- 2016-10-07 AR ARP160103074A patent/AR106293A1/es unknown
- 2016-10-07 WO PCT/US2016/055980 patent/WO2017062763A1/en active Application Filing
- 2016-10-07 JP JP2018517509A patent/JP7021080B2/ja active Active
- 2016-10-07 CA CA3000881A patent/CA3000881C/en active Active
- 2016-10-07 ES ES16854420T patent/ES2898705T3/es active Active
- 2016-10-07 MA MA045761A patent/MA45761A/fr unknown
- 2016-10-07 AU AU2016335765A patent/AU2016335765B2/en active Active
- 2016-10-07 UA UAA201804942A patent/UA123948C2/uk unknown
- 2016-10-07 US US15/288,390 patent/US11034717B2/en active Active
- 2016-10-07 EA EA201890899A patent/EA038665B1/ru unknown
- 2016-10-07 EP EP21192609.2A patent/EP3981779A1/en not_active Withdrawn
-
2018
- 2018-04-05 CL CL2018000883A patent/CL2018000883A1/es unknown
- 2018-04-05 SV SV2018005662A patent/SV2018005662A/es unknown
- 2018-04-06 CO CONC2018/0003728A patent/CO2018003728A2/es unknown
- 2018-04-10 PH PH12018500777A patent/PH12018500777A1/en unknown
- 2018-04-19 EC ECIEPI201830284A patent/ECSP18030284A/es unknown
- 2018-05-03 ZA ZA2018/02901A patent/ZA201802901B/en unknown
- 2018-10-08 HK HK18112762.1A patent/HK1253558A1/zh unknown
-
2019
- 2019-09-20 JP JP2019171488A patent/JP2019210297A/ja active Pending
-
2021
- 2021-05-14 US US17/320,286 patent/US20210269475A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1253558A1 (zh) | 法尼醇x受體調節劑 | |
| IL285318A (en) | Estrogen receptor modulators | |
| MA43382A (fr) | Modulateurs des récepteurs des chimiokines | |
| GB201514875D0 (en) | Receptor | |
| HK1252163A1 (zh) | 受體 | |
| HK1255160A1 (zh) | 取代的4-氮雜吲哚以及它們作為glun2b受體調節劑的用途 | |
| IL274537A (en) | nuclear receptor modulators | |
| ZA201700342B (en) | Novel glp-1 receptor modulators | |
| PL3303291T3 (pl) | Modulatory ROR-gamma | |
| IL251067A0 (en) | p2x7 modulators | |
| PL3303293T3 (pl) | Modulatory ROR-gamma | |
| PL3303290T3 (pl) | Modulatory ROR-gamma | |
| HRP20190024T1 (hr) | Derivati hidroksialkil-piperazina kao modulatori receptora cxcr3 | |
| PL3319942T3 (pl) | MODULATORY ROR-GAMMA (RORγ) | |
| GB201716468D0 (en) | Modulators | |
| IL266261A (en) | ror-gamma modulators | |
| IL252565B (en) | New receptor modulators | |
| HK1254769A1 (zh) | 包含s1p受體調節劑的組合物 | |
| GB2563095B (en) | Modulators | |
| GB201702926D0 (en) | Modulators | |
| GB201512714D0 (en) | Receptor modulator compounds | |
| GB201512054D0 (en) | G-spot vibrator | |
| GB201400215D0 (en) | Modulators |